{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:05:43Z","timestamp":1785326743049,"version":"3.55.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Cancer immunotherapy has shown significant promise in certain patient populations, but further advancements are needed to extend its benefits to a wider range of patients. Clustered regularly interspaced short palindromic repeats (CRISPR)-based editing has rapidly evolved in recent years, enabling its transition into direct therapeutic applications. This review summarizes recent progress in applying CRISPR systems\n                    <jats:italic>in vivo<\/jats:italic>\n                    for cancer immunotherapy, focusing on approaches that target cancer cells and the tumor microenvironment, as well as those that directly engineer immune cell populations themselves. Novel CRISPR editing platforms and strategies enabling multiplexed editing have also recently demonstrated promising impacts on driving antitumor immunity, however, the platforms investigated are still in the early stages and further investigation will be needed to robustly assess the potential for clinical translation. Future work can expand the array of therapeutic targets by incorporating data from functional genomics and must also carefully evaluate both editing modalities and delivery systems to optimize efficacy, safety, and scalability.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1872510","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:20:20Z","timestamp":1785324020000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["In vivo CRISPR editing for cancer immunotherapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Cole W.","family":"Christopher","sequence":"first","affiliation":[{"name":"Vaccine and Immunotherapy Center, The Wistar Institute","place":["Philadelphia, PA, United States"]},{"name":"Ellen and Ronald Caplan Cancer Center, The Wistar Institute","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Vaccine and Immunotherapy Center, The Wistar Institute","place":["Philadelphia, PA, United States"]},{"name":"Ellen and Ronald Caplan Cancer Center, The Wistar Institute","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy\u2014current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing cytokines and chemokines for cancer therapy","volume":"19","author":"Propper","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03125-y","article-title":"T cell engagers: expanding horizons in oncology and beyond","volume":"133","author":"Albayrak","year":"2025","journal-title":"Br J Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.add8643","article-title":"CRISPR technology: A decade of genome editing is only the beginning","volume":"379","author":"Wang","year":"2023","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.01.042","article-title":"Past, present, and future of CRISPR genome editing technologies","volume":"187","author":"Pacesa","year":"2024","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23730","article-title":"CRISPR knock out of programmed cell death protein 1 enhances anti-tumor activity of cytotoxic T lymphocytes","volume":"9","author":"Zhao","year":"2018","journal-title":"Oncotarget"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","article-title":"Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells","volume":"56","author":"Agarwal","year":"2023","journal-title":"Immunity"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202401632","article-title":"Lipid nanoparticles for delivery of CRISPR gene editing components","volume":"10","author":"Wu","year":"2026","journal-title":"Small Methods"},{"key":"B12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41587-025-02945-w","article-title":"Targeted delivery of genome editors in vivo","volume":"44","author":"Ngo","year":"2026","journal-title":"Nat Biotechnol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102666","article-title":"Advancing gene editing therapeutics: clinical trials and innovative delivery systems across diverse diseases","volume":"36","author":"Raigani","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2019.100789","article-title":"Sharpening the molecular scissors: advances in gene-editing technology","volume":"23","author":"Broeders","year":"2020","journal-title":"iScience"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.7b00680","article-title":"The promise and challenge of in vivo delivery for genome therapeutics","volume":"13","author":"Wilson","year":"2018","journal-title":"ACS Chem Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic in vivo delivery of gene editing agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01174-1","article-title":"In vivo CAR engineering for immunotherapy","volume":"25","author":"Li","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01291-5","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","volume":"25","author":"Bot","year":"2026","journal-title":"Nat Rev Drug Discov"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2026.01.007","article-title":"In vivo CAR T cell engineering: design principles and open questions","author":"Aalipour","year":"2026","journal-title":"Trends Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA\u2013guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.09.038","article-title":"Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system","volume":"163","author":"Zetsche","year":"2015","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102636","article-title":"Off-target effects in CRISPR-Cas genome editing for human therapeutics: progress and challenges","volume":"36","author":"Kalter","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01377-0","article-title":"Frequent aneuploidy in primary human T cells after CRISPR\u2013Cas9 cleavage","volume":"40","author":"Nahmad","year":"2022","journal-title":"Nat Biotechnol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.06.044","article-title":"CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes","volume":"154","author":"Gilbert","year":"2013","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2013.122","article-title":"Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system","volume":"23","author":"Cheng","year":"2013","journal-title":"Cell Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf5573","article-title":"C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector","volume":"353","author":"Abudayyeh","year":"2016","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41578-024-00725-7","article-title":"CRISPR\u2013Cas9 delivery strategies for the modulation of immune and non-immune cells","volume":"10","author":"Alsaiari","year":"2024","journal-title":"Nat Rev Mater"},{"key":"B31","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1186\/s12885-025-14093-0","article-title":"Adeno-associated virus-clustered regularly interspaced short palindromic repeats\/cas9-mediated ovarian cancer treatment targeting PD-L1","volume":"25","author":"Yahata","year":"2025","journal-title":"BMC Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.immuni.2025.01.009","article-title":"In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313","volume":"58","author":"Nyberg","year":"2025","journal-title":"Immunity"},{"key":"B33","doi-asserted-by":"publisher","first-page":"712\u201321","DOI":"10.1038\/s41586-026-10235-x","article-title":"In vivo site-specific engineering to reprogram T cells","volume":"652","author":"Nyberg","year":"2026","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-nanoparticle-based delivery of CRISPR\/Cas9 genome-editing components","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol Pharm"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajps.2022.07.005","article-title":"Lipid nanoparticle-mediated CRISPR\/Cas9 gene editing and metabolic engineering for anticancer immunotherapy","volume":"17","author":"Ju","year":"2022","journal-title":"Asian J Pharm Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-022-01122-3","article-title":"Enhancing CRISPR\/Cas gene editing through modulating cellular mechanical properties for cancer therapy","volume":"17","author":"Zhang","year":"2022","journal-title":"Nat Nanotechnol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2407262","DOI":"10.1002\/advs.202407262","article-title":"CD47 knock\u2010out using CRISPR\u2010Cas9 RNA lipid nanocarriers results in reduced mesenchymal glioblastoma growth in vivo","volume":"12","author":"Rouatbi","year":"2025","journal-title":"Adv Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"eady5579","DOI":"10.1126\/sciadv.ady5579","article-title":"A multistep platform identifies spleen-tropic lipid nanoparticles for in vivo T cell\u2013targeted delivery of gene-editing proteins","volume":"11","author":"Lu","year":"2025","journal-title":"Sci Adv"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.08.030","article-title":"Optimized lipid nanoparticles enable effective CRISPR\/Cas9-mediated gene editing in dendritic cells for enhanced immunotherapy","volume":"15","author":"Mao","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202004879","article-title":"Photo\u2010enhanced CRISPR\/Cas9 system enables robust PD\u2010L1 gene disruption in cancer cells and cancer stem\u2010like cells for efficient cancer immunotherapy","volume":"16","author":"Zhao","year":"2020","journal-title":"Small"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202006003","article-title":"Reprogramming the tumor microenvironment through second\u2010near\u2010infrared\u2010window photothermal genome editing of PD\u2010L1 mediated by supramolecular gold nanorods for enhanced cancer immunotherapy","volume":"33","author":"Tang","year":"2021","journal-title":"Adv Mater"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2415100122","article-title":"A versatile immunomodulated nanoCRISPR converter augments the susceptibility and visibility of tumors to the immune system","volume":"122","author":"Li","year":"2025","journal-title":"Proc Natl Acad Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202100292","article-title":"Programmable unlocking nano\u2010matryoshka\u2010CRISPR precisely reverses immunosuppression to unleash cascade amplified adaptive immune response","volume":"8","author":"Yang","year":"2021","journal-title":"Adv Sci"},{"key":"B44","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s41467-024-44941-9","article-title":"Bacterial protoplast-derived nanovesicles carrying CRISPR-Cas9 tools re-educate tumor-associated macrophages for enhanced cancer immunotherapy","volume":"15","author":"Zhao","year":"2024","journal-title":"Nat Commun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-02085-z","article-title":"In vivo human T cell engineering with enveloped delivery vehicles","volume":"42","author":"Hamilton","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01086-x","article-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","volume":"55","author":"Lee","year":"2023","journal-title":"Exp Mol Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"10218","DOI":"10.1038\/s41467-024-54292-0","article-title":"In vivo gene editing of T-cells in lymph nodes for enhanced cancer immunotherapy","volume":"15","author":"Qu","year":"2024","journal-title":"Nat Commun"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0500-4","article-title":"Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity","volume":"20","author":"Wang","year":"2019","journal-title":"Nat Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02535-2","article-title":"Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy","volume":"43","author":"Zhang","year":"2025","journal-title":"Nat Biotechnol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01527-4","article-title":"Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases","volume":"41","author":"Yarnall","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41551-024-01227-1","article-title":"Efficient site-specific integration of large genes in mammalian cells via continuously evolved recombinases and prime editing","volume":"9","author":"Pandey","year":"2024","journal-title":"Nat BioMed Eng"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1126\/science.adt5199","article-title":"Programmable gene insertion in human cells with a laboratory-evolved CRISPR-associated transposase","volume":"388","author":"Witte","year":"2025","journal-title":"Science"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1872510\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:20:22Z","timestamp":1785324022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1872510\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2026.1872510"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1872510","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1872510"}}